Wall Street Zen Upgrades Grifols (NASDAQ:GRFS) to "Strong-Buy"

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Monday.

Separately, JPMorgan Chase & Co. raised their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th.

Grifols Price Performance

GRFS traded up $0.36 on Monday, hitting $9.75. 1,507,848 shares of the company's stock traded hands, compared to its average volume of 1,082,026. The firm has a market cap of $6.70 billion, a price-to-earnings ratio of 8.33, a P/E/G ratio of 0.34 and a beta of 0.55. The company's 50 day simple moving average is $8.42 and its 200-day simple moving average is $7.75. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13. Grifols has a one year low of $6.19 and a one year high of $9.96.

Hedge Funds Weigh In On Grifols

Several institutional investors have recently added to or reduced their stakes in GRFS. Versant Capital Management Inc purchased a new position in shares of Grifols in the 1st quarter worth approximately $28,000. Tower Research Capital LLC TRC boosted its holdings in shares of Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 6,335 shares during the period. First Trust Advisors LP purchased a new position in shares of Grifols in the 4th quarter worth approximately $75,000. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Grifols in the 4th quarter worth approximately $77,000. Finally, Ballentine Partners LLC purchased a new position in shares of Grifols in the 1st quarter worth approximately $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.